Metabolism & Endocrinology

Metabolism & Endocrinology Research Reagents

Metabolic and endocrine disorders — diabetes, obesity, thyroid dysfunction, and osteoporosis — affect billions of people worldwide and are among the fastest-growing areas of biomedical research. The success of GLP-1 receptor agonists (semaglutide, tirzepatide) in diabetes and obesity has transformed the therapeutic landscape, while advances in incretin biology, adipokine signaling, and bone remodeling continue to reveal new drug targets and biomarkers. Studying these pathways requires well-characterized hormones, receptor proteins, and detection antibodies.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key metabolic and endocrine research targets — pancreatic hormones, incretin axis components, adipokines, pituitary/thyroid hormones, and bone metabolism regulators. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom development.

Key Research Areas

Diabetes & Insulin Signaling — Insulin, insulin receptor, GLP-1/GIP incretin hormones, and downstream signaling components (IRS1/2, GLUT4). The incretin axis is the hottest area in metabolic drug development — GLP-1 receptor agonists and dual GLP-1/GIP agonists (tirzepatide) are reshaping treatment for type 2 diabetes and obesity. Recombinant hormones and receptor proteins support binding assays, bioactivity studies, and ADA reagent generation.
→ Browse Diabetes & Insulin Signaling products

Thyroid & Pituitary Hormones — TSH, T3/T4, growth hormone, prolactin, FSH, LH, and ACTH. Thyroid function testing is one of the highest-volume immunoassay categories in clinical diagnostics, and pituitary hormones are central to endocrine axis regulation. Recombinant hormone proteins serve as immunoassay calibrators and standards.
→ Browse Thyroid & Pituitary Hormone products

Adipokines & Obesity — Adipose tissue-secreted hormones including FGF21, adiponectin, leptin, resistin, and RBP4. Adipokines regulate insulin sensitivity, energy expenditure, and systemic inflammation. FGF21 is an emerging therapeutic target, with FGF21 analogs in clinical development for NASH and metabolic syndrome.
→ Browse Adipokine & Obesity products

Bone & Mineral Metabolism — RANKL/OPG axis, sclerostin, PTH, osteocalcin, and Cathepsin K. The RANKL pathway is the target of denosumab (anti-RANKL) for osteoporosis; anti-sclerostin (romosozumab) represents the newest class of bone-forming therapy. Recombinant proteins and antibodies support osteoclast differentiation assays, bone resorption studies, and drug target validation.
→ Browse Bone & Mineral Metabolism products

References

1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. DOI

2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. DOI

3. Kuro-o M. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15(1):27-44. DOI

4. Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-1543. DOI